Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Benjamin Stone currently holds 77,159 shares of First Tracks Biotherapeutics, Inc. (TRAX), valued at approximately $0. This represents their equity stake as Chief Business Officer.
Based on SEC Form 4 filings, Benjamin Stone has been a net neutral trader of TRAX stock. They have purchased $0 and sold $0 worth of shares.
Benjamin Stone's most recent insider trade was on Aug 2, 2026, when they sold 60,492 shares at $0.00 per share.
Benjamin Stone serves as Chief Business Officer at First Tracks Biotherapeutics, Inc. (TRAX). They have executed 1 insider transactions totaling $0 over their tenure at the company.
Benjamin Stone holds the position of Chief Business Officer at First Tracks Biotherapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 1 years and currently hold a stake valued at $0.
Benjamin Stone has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Benjamin Stone was on Aug 2, 2026, when they purchased $0 worth of TRAX shares. This transaction involved 60,492 shares at N/A per share.
Benjamin Stone currently owns 77,159 shares of First Tracks Biotherapeutics, Inc. (TRAX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Benjamin Stone's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Benjamin Stone has 1 Form 4 filings on record as an insider at First Tracks Biotherapeutics, Inc..
Set alerts for Benjamin Stone and 40,000+ other insiders.